Advanced Ovarian Cancer: A Prospective Randomised Trial of Chlorambucil Versus Combined Cyclophosphamide and Cis-diamminedichloroplatinum
Generate an AI Snapshot to get a quick, structured summary of this paper.
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A response was associated with a longer median survival but no survival advantage was demonstrated for patients who received cyclophosphamide/cis DDP and a larger study is needed to evaluate fully the potential of regimens containing cis DDP in the management of advanced ovarian cancer.
Abstract
Thirty-seven patients with advanced ovarian cancer were treated in a prospective, randomised trial comparing chlorambucil with a combination of cyclophosphamide and cis-diamminedichloroplatinum (cis DDP). Treatment with the combination was associated with an increased overall response rate (69% versus 23%) (p = 0.04). A response was associated with a longer median survival but no survival advantage was demonstrated for patients who received cyclophosphamide/cis DDP. A larger study is needed to evaluate fully the potential of regimens containing cis DDP in the management of advanced ovarian cancer.